Screening differences and risk of cervical cancer in inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 28, Issue 5, 2008, Pages 598-605

  Hutfless, S ^a,b   Fireman, B ^a   Kane, S ^c   Herrinton, L J ^a  

^a DIVISION OF RESEARCH   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMINOSALICYLIC ACID DERIVATIVE; AZATHIOPRINE; BALSALAZIDE; CORTICOSTEROID; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; OLSALAZINE; SALAZOSULFAPYRIDINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER REGISTRY; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; ENTERITIS; FEMALE; HUMAN; IMMUNE DEFICIENCY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PREVALENCE; PRIORITY JOURNAL; UTERINE CERVIX CANCER;

ADOLESCENT; ADULT; AGED; CALIFORNIA; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MALE; MASS SCREENING; MIDDLE AGED; RISK ASSESSMENT; UTERINE CERVICAL NEOPLASMS;

EID: 48449088876     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03766.x     Document Type: Article

References (26)

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5. version 2.0 ed. Lyon : IARCPress, 2004.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007 57 : 43 66.
3. Gustafsson L, Ponten J, Bergstrom R, Adami HO. International incidence rates of invasive cervical cancer before cytological screening. Int J Cancer 1997 71 : 159 65.
4. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007 370 : 890 907.
5. Wallace SV, Carlin EM. HIV in cervical cancer. Int J STD AIDS 2001 12 : 283 5.
6. Busnach G, Piselli P, Arbustini E, et al. Immunosuppression and cancer: a comparison of risks in recipients of organ transplants and in HIV-positive individuals. Transplant Proc 2006 38 : 3533 5.
7. Tam LS, Chan AY, Chan PK, Chang AR, Li EK. Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus: association with human papillomavirus infection. Arthritis Rheum 2004 50 : 3619 25.
8. Bhatia J, Bratcher J, Korelitz B, et al. Abnormalities of uterine cervix in women with inflammatory bowel disease. World J Gastroenterol 2006 12 : 6167 71.
9. Kane SV, Khatibi B, Reddy D. Higher incidence of abnormal pap smears in women with inflammatory bowel disease. Am J Gastroenterol 2008 103 : 63 6.
10. U.S. Preventive Services Task Force. Screening for Cervical Cancer: Recommendations and Rationale. Washington, DC : Office of Disease Prevention and Health Promotion. 2003.
11. Herrinton LJ, Liu L, Lafata JE, et al. Estimation of the period prevalence of inflammatory bowel disease among nine health plans using computerized diagnoses and outpatient pharmacy dispensings. Inflamm Bowel Dis 2007 13 : 451 61.
12. Karter AJ, Moffet HH, Liu J, et al. Achieving good glycemic control: initiation of new antihyperglycemic therapies in patients with type 2 diabetes from the Kaiser Permanente Northern California Diabetes Registry. Am J Manag Care 2005 11 : 262 70.
13. Mahid SS, Minor KS, Soto RE, Hornung CA, Galandiuk S. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc 2006 81 : 1462 71.
14. Plummer M, Herrero R, Franceschi S, et al. Smoking and cervical cancer: pooled analysis of the IARC multi-centric case - control study. Cancer Causes Control 2003 14 : 805 14.
15. Gordon NP. How Does the Adult Kaiser Permanente Membership in Northern California Compare with the Larger Community? Oakland, CA : Kaiser Permanente Division of Research, 2006.
16. Greenland S, Finkle WD. A critical look at methods for handling missing covariates in epidemiologic regression analyses. Am J Epidemiol 1995 142 : 1255 64.
17. Rubin DB. Multiple Imputation for in Surveys. New York : Wiley, 1987.
18. McNutt LA, Wu C, Xue X, Hafner JP. Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol 2003 157 : 940 3.
19. Venkatesan T, Beaulieu DB, Ferrer V, et al. Abnormal PAP smear, cervical dysplasia and immunomodulator therapy in women with inflammatory bowel disease (IBD). Gastroenterology 2006 130 : A3.
20. Goldacre MJ, Wotton CJ, Yeates D, Seagroatt V, Jewell D. Cancer in patients with ulcerative colitis, Crohn's disease and coeliac disease: record linkage study. Eur J Gastroenterol Hepatol 2008 20 : 297 304.
21. Connell WR, Kamm MA, Dickson M, Balkwill AM, Ritchie JK, Lennard-Jones JE. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994 343 : 1249 52.
22. Winther KV, Jess T, Langholz E, Munkholm P, Binder V. Survival and cause-specific mortality in ulcerative colitis: follow-up of a population-based cohort in Copenhagen County. Gastroenterology 2003 125 : 1576 82.
23. Jess T, Winther KV, Munkholm P, Langholz E, Langholz E, Binder V. Mortality and causes of death in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Gastroenterology 2002 122 : 1808 14.
24. Selby L, Kane S, Wilson J, et al. Receipt of preventive health services by IBD patients is significantly lower than by primary care patients. Inflamm Bowel Dis 2008 14 : 253 8.
25. Rowhani-Rahbar A, Hawes SE, Sow PS, et al. The impact of HIV status and type on the clearance of human papillomavirus infection among Senegalese women. J Infect Dis 2007 196 : 887 94.
26. Castle PE. Beyond human papillomavirus: the cervix, exogenous secondary factors, and the development of cervical precancer and cancer. J Low Genit Tract Dis 2004 8 : 224 30.